The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Phase I study of PHE885 CAR T-cell therapy in R/R multiple myeloma
Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, describes the results of a Phase I dose-escalation study evaluating PHE885, a BCMA-directed chimeric antigen receptor (CAR) T-cell, in relapsed/refractory (R/R) multiple myeloma (NCT04318327). PHE885 is manufactured using the T-Charge™️ platform which enables the CAR-T product to be manufactured in less than two days, providing a significant advantage over other existing CAR T-cell products. The study reported a response rate (RR) of 75% in patients who received 2.5 million cells, and reached 100% in patients who received 5 and 10 million cells. With a median follow-up of 3.5 months, 8 of 15 patients have an ongoing response to treatment with PHE885. Further results on response durability and progression-free survival (PFS) are eagerly awaited. Moreover, all 15 patients experienced cytokine release syndrome (CRS), but only 13% had grade 3 or higher toxicity, and 4 patients had neurotoxicity. Dr Munshi explains that the short CAR-T production time allows to predict CRS accurately. In addition, a naïve-like T-cell phenotype was observed in patients achieving partial response (PR) following infusion and was associated with a better overall outcome. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
